VASO Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VASO Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.10M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $86.77M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $81.02M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $79.29M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $75.58M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $69.85M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $75.52M | May 5, 2021 |
| FY2019 | Dec 31, 2018 | $73.98M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $72.79M | Apr 15, 2019 |
| FY2015 | Dec 31, 2015 | $57.08M | Mar 30, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $75.58M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $69.85M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $75.52M | May 5, 2021 |
| FY2019 | Dec 31, 2018 | $73.98M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $72.79M | Apr 15, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $72.79M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $72.59M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $57.08M | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $34.95M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $32.89M | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | $29.24M | Mar 27, 2014 |
| FY2012 | Dec 31, 2011 | $23.49M | Apr 1, 2013 |
| FY2012 | May 31, 2011 | $16.37M | Apr 1, 2013 |
| FY2012 | Dec 31, 2010 | $8.74M | Apr 1, 2013 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.67M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $52.05M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $50.59M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $47.90M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $43.13M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $38.57M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $42.43M | May 5, 2021 |
| FY2019 | Dec 31, 2018 | $41.12M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $40.73M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $41.50M | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.57M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $951.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.81M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.29M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.10M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $358.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($382.0K) | May 5, 2021 |
| FY2019 | Dec 31, 2018 | ($3.73M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($4.54M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $820.0K | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.89M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $285.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.20M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.45M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.82M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $772.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $591.0K | May 5, 2021 |
| FY2019 | Dec 31, 2018 | ($3.72M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($3.83M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $1.56M | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $728.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $851.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $755.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $605.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.72M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $745.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $813.0K | May 5, 2021 |
| FY2019 | Dec 31, 2018 | $886.0K | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $945.0K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $530.0K | Apr 2, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.20M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $48.98M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $45.08M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $40.84M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $38.59M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $37.05M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $41.03M | May 5, 2021 |
| FY2019 | Dec 31, 2018 | $43.96M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $43.62M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $39.41M | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.27M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.28M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.30M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $14.42M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.82M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.93M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.33M) | May 5, 2021 |
| FY2019 | Dec 31, 2018 | ($1.45M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.60M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $5.22M | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $566.0K | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $415.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.00M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.21M | May 5, 2021 |
| FY2019 | Dec 31, 2018 | $2.59M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $2.37M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $1.87M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $893.0K | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $389.0K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $228.0K | Mar 30, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.35M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $82.94M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $75.76M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $71.65M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $52.36M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $50.38M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $54.36M | May 5, 2021 |
| FY2019 | Dec 31, 2018 | $50.47M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $56.78M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $57.38M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.43M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $27.70M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $26.84M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $22.07M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $11.08M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $5.09M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $4.31M | Mar 31, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.96M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $15.55M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $15.59M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $15.61M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $15.72M | Apr 1, 2024 |
| FY2021 | Dec 31, 2020 | $15.69M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $17.27M | Mar 31, 2022 |
| FY2021 | Dec 31, 2018 | $17.31M | Mar 31, 2022 |
| FY2019 | Dec 31, 2017 | $17.47M | Apr 14, 2020 |
| FY2018 | Dec 31, 2016 | $17.28M | Apr 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($32.51M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($34.08M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($35.03M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($39.84M) | Apr 1, 2024 |
| FY2023 | Jan 1, 2022 | $229.00M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($50.90M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($57.00M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($57.36M) | May 5, 2021 |
| FY2020 | Dec 31, 2018 | ($56.98M) | May 5, 2021 |
| FY2018 | Dec 31, 2017 | ($52.33M) | Apr 15, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.05M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $26.27M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $11.34M | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | $11.82M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $6.03M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $6.82M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $2.12M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $2.67M | May 5, 2021 |
| FY2019 | Dec 31, 2017 | $5.25M | Apr 14, 2020 |
| FY2018 | Dec 31, 2016 | $7.09M | Apr 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $15.0K | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $23.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.78M | Mar 31, 2022 |
| FY2018 | Dec 31, 2018 | $10.55M | Apr 15, 2019 |
| FY2017 | Dec 31, 2017 | $8.90M | Apr 2, 2018 |
| FY2016 | Dec 31, 2016 | $9.57M | Mar 30, 2017 |
| FY2015 | Dec 31, 2015 | $7.33M | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $1.18M | Mar 30, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | May 5, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Apr 14, 2020 |
| FY2015 | Dec 31, 2015 | 0 | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Mar 30, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2020 | Dec 31, 2020 | 0 | May 5, 2021 |
| FY2020 | Dec 31, 2019 | 0 | May 5, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Apr 14, 2020 |
| FY2015 | Dec 31, 2015 | 0 | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Mar 30, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 175.95M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 175.70M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 175.32M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 175.13M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 175.13M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 174.94M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 173.44M | May 5, 2021 |
| FY2019 | Dec 31, 2018 | 167.11M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | 165.43M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | 163.50M | Apr 2, 2018 |